Nuclidium AG products

Nuclidium AG leverages the unique properties of copper radionuclides to advance precision radiotherapy and diagnostics. Their proprietary CuTrace™ platform combines copper nuclides with tumor-specific molecules, creating diagnostic and therapeutic pairs designed to optimize the safety and efficacy profile in cancer treatment. These radionuclides, including 61Cu for diagnostics and 67Cu for therapeutics, are integral in developing highly precise cancer-targeting methods. The platform features several advantageous properties such as favorable dosimetry, high imaging quality, and reduced radiation burden, which are crucial in detecting small metastases. Furthermore, the efficient production and supply chain of these copper-based radiopharmaceuticals enhance treatment accessibility worldwide, as no nuclear reactors are required, and radioactive waste is minimized. Nuclidium AG is pioneering innovations that elevate the standards for precision in oncology.